ZEDRA
7.1.2020 09:02:07 CET | Business Wire | Press release
ZEDRA Group (“ZEDRA”), the global specialist in Corporate, Fund and ‘Active-Wealth’ services and Corsair Capital LLC (“Corsair”), one of the leading private equity firms focused on the financial and business services industries, today announced the successful close of Corsair’s majority investment in ZEDRA Group. The transaction, which was first announced on November 28, 2018, has been approved by all relevant regulatory authorities.
Following the close of the transaction, Bart Deconinck, a highly experienced industry figure who previously has been CEO of Intertrust and was a founder of Vistra before going on to co found Zedra four years ago, has been appointed Group Executive Chairman. In addition, Ivo Hemelraad, formerly Zedra Group Director Corporate Funds & Legal, will assume the role of Group Chief Executive Officer.
ZEDRA delivers tailored high quality diversified active-wealth solutions to its clients, which include high net worth individuals and their families, as well as medium to large sized companies, asset managers and their investors. ZEDRA’s full range of services is designed to preserve and protect the real value of clients’ assets and support them in unlocking growth and expansion.
Raja Hadji-Touma and Derrick Estes, Managing Directors at Corsair Capital said, “ZEDRA is a unique firm with unparalleled capabilities, and we are pleased to have closed this exciting investment. We look forward to partnering with an ambitious management team, led by Bart Deconinck, with a proven track record of building leading companies in the sector. We believe our investment and financial services expertise, along with the unmatched global network we bring to bear, will help support continued rapid growth at ZEDRA.”
Over the last 12 months, ZEDRA has made a number of important acquisitions, creating an expanded platform with over 570 staff in a 16 office network covering 13 jurisdictions across Asia, Oceania, the Americas and Europe. As the Company continues to integrate these acquisitions, ZEDRA is even better-placed to continue creating and delivering bespoke trust, corporate and fund services solutions for clients including high-net-worth individuals and their families, international corporations, institutional investors and entrepreneurs.
Bart Deconinck, Group Executive Chairman added, “Today marks the start of the next stage of ZEDRA‘s ambitious growth plans. Powered by a combination of the resources and expertise of Corsair, together with ZEDRA’s considerable experience in the sector, we are looking forward to a period of rapid growth and expansion of the range of services we offer to our clients. The major acquisitions we have made over the past year expand our footprint across Switzerland, the Nordic countries, Cayman and offshore UK jurisdictions, bringing additional clients and staff into the ZEDRA family.”
Under its ‘Active - Wealth’ umbrella, ZEDRA provides a single point of contact for the administration of a wide range of assets for families with diversified investments, including the administration of any relevant structures they require, such as their corporate investment ventures, single-family offices, or private funds for various family members.
Ivo Hemelraad commented: “We are delighted to have completed this transaction and to begin our partnership with Corsair Capital. Their commitment and support to ZEDRA’ S growth as well as to our people are an exciting step for ZEDRA to further enhance our offering and position in the industry.”
Editor notes
https://www.zedra.com/boilerplate/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005091/en/
Contact:
Guy Stephenson Nacelle 020 8333 9125
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom